Clinical Trial Update: A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) [NA]

View source ↗

Summary

This document reports a completed 16-week evaluation of the Novartis Health Management Tool in patients with age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Novartis Health Management Tool

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age Related Macular Degeneration (AMD) | NA | Status: COMPLETED